智通财经APP获悉，丽珠医药(01513)涨近3%，截至发稿，涨2.74%，报28.2港元，成交额3155.53万港元。
消息面上，丽珠医药发布公告，于2025年5月22日，该公司间接全资附属LIAN SGP HOLDING PTE. LTD.拟向SK Investment、Sunrise及KBA收购Imexpharm Corporation已发行股份的64.81%，总现金代价为 5,730,815,426,000越南盾(按协议签署当日汇率换算，约为人民币15.87亿元，港币17.28 亿元)。交割后，目标公司将成为本公司一间间接非全资附属公司，其财务业绩将并入该集团财务报表。
据悉，目标公司是一家越南制药公司，主要从事药品的研发、生产和销售，其产品主要包括抗生素、心脑血管药物等。本次收购为集团进一步拓展海外市场奠定坚实基础，支持其在医药领域国际化及可持续发展的长期战略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.